Center for Genitourinary (GU) Cancer Care

When can­cer touch­es your life, you deserve clear answers, a plan that fits you, and a team that moves quick­ly. At the Bri­an Moran Can­cer Insti­tute, our GU spe­cial­ists care for can­cers of the prostate, blad­der, kid­ney, and tes­ti­cles with an approach built on per­son­al­iza­tion, access, and outcomes.

What makes our GU can­cer care different

Mul­ti­dis­ci­pli­nary care, all in one place

Your care is led by a coor­di­nat­ed team of experts in urol­o­gy, med­ical oncol­o­gy, sur­gi­cal oncol­o­gy, and radi­a­tion oncol­o­gy who work side by side:

• One team, one plan: Your case is reviewed togeth­er — often the same day — so you leave with a clear, uni­fied plan.
• Lead­ers in their fields: Board-cer­ti­fied and fel­low­ship-trained spe­cial­ists focused on GU can­cers bring advanced skills in robot­ic surgery, pre­ci­sion radi­a­tion, sys­temic ther­a­pies, and organ-pre­serv­ing options.
• Faster answers: Mul­ti­dis­ci­pli­nary clin­ics and case con­fer­ences (tumor boards) stream­line deci­sions and reduce wait times between steps.
• Seam­less coor­di­na­tion: Nurse nav­i­ga­tors con­nect appoint­ments, imag­ing, labs, and treat­ments so noth­ing falls through the cracks.

Per­son­al­ized can­cer care from the start

Your care begins with under­stand­ing you, not just your diag­no­sis. We use advanced screen­ing tools like 4Kscore, MyProstateScore 2.0, prostate MRI, and can­cer-spe­cif­ic PET/CT scans to bet­ter assess risk and avoid unnec­es­sary pro­ce­dures. Our team applies pre­ci­sion test­ing, includ­ing genet­ic and genom­ic analy­sis through part­ners like Tem­pus, to guide each treat­ment deci­sion. AI-sup­port­ed insights help us tai­lor your plan even fur­ther, ensur­ing you get the right care at the right time.

With our mul­ti­dis­ci­pli­nary clin­ics, you can meet your urol­o­gist, med­ical oncol­o­gist, radi­a­tion oncol­o­gist, and nurse nav­i­ga­tor togeth­er so your plan comes togeth­er quick­ly and seamlessly.

Aca­d­e­m­ic-lev­el options, close to home

• Clin­i­cal tri­als avail­able for eli­gi­ble patients — bring­ing next-gen­er­a­tion ther­a­pies into the community.
• Coor­di­nat­ed sup­port wrapped around you and your fam­i­ly (nurse nav­i­ga­tion, rehab, nutri­tion, men­tal health sup­port), not just dur­ing treat­ment but through recovery.

Treat­ments we offer

We pro­vide the full range of stan­dard ther­a­pies — plus options few cen­ters offer — always with an eye toward organ preser­va­tion and qual­i­ty of life.

Prostate can­cer

We offer organ-pre­serv­ing focal ther­a­pies such as cryother­a­py, NanoKnife®, and HIFU for select tumors; pre­cise radi­a­tion options (IMRT/IGRT/SBRT) that pro­tect healthy tis­sue; robot­ic prosta­te­c­to­my by fel­low­ship-trained sur­geons; and per­son­al­ized sys­temic treat­ments like hor­mone ther­a­py, tar­get­ed agents, and radi­oli­gand ther­a­py (Plu­vic­to®).

Blad­der cancer

When­ev­er pos­si­ble, we focus on blad­der preser­va­tion through intrav­es­i­cal ther­a­pies (BCG, Ank­ti­va™, Adsti­ladrin®) and com­bined chemora­di­a­tion. For inva­sive dis­ease, our team per­forms robot­ic cys­tec­to­my with intra­cor­po­re­al uri­nary diver­sions (ileal con­duit, neoblad­der, or Indi­ana pouch). We also offer sys­temic options, includ­ing chemother­a­py, immunother­a­py, and genom­ic-based treatments.

Kid­ney cancer

Our approach empha­sizes nephron-spar­ing surgery (robot­ic par­tial nephrec­to­my), min­i­mal­ly inva­sive abla­tion through inter­ven­tion­al radi­ol­o­gy, and tar­get­ed or immunother­a­pies guid­ed by tumor sequenc­ing for more options.

Tes­tic­u­lar cancer

We pro­vide advanced surgery (includ­ing retroperi­toneal lymph node dis­sec­tion) and mod­ern chemother­a­py pro­to­cols, with sur­vivor­ship care that sup­ports fer­til­i­ty and long-term wellness.

If you’ve heard of a treat­ment and won­der whether we offer it, it’s like­ly we do. We’re hap­py to con­firm specifics like IMRT/IGRT/SBRT, robot­ic approach­es, and inter­ven­tion­al radi­ol­o­gy options and how they fit your situation.

Clin­i­cal tri­als & research

Clin­i­cal tri­als are an impor­tant way we per­son­al­ize care. For eli­gi­ble patients, tri­als can open access to promis­ing, non-stan­dard ther­a­pies. Your team will review avail­able GU tri­als with you and coor­di­nate enroll­ment when it’s a good fit.

Cur­rent GU can­cer tri­als and research: 

• NCT07225946 — Bri­an Myre, MD — A Phase 3 Ran­dom­ized, Open-label Study of JNJ-78278343, a T Cell-redi­rect­ing agent tar­get­ing Human Kallikrein 2, with Doc­etax­el Ver­sus Doc­etax­el for Metasta­t­ic Cas­tra­tion-Resis­tant Prostate Cancer
• NCT06533644 — Bri­an Myre, MD — A Phase 2a Mul­ti­cen­ter Dose Esca­la­tion and Dose Opti­miza­tion Study of SYNC‑T Ther­a­py SV-102 for Patients with Metasta­t­ic Cas­tra­tion-Resis­tant Prostate Can­cer (mCR­PC)
• NCT06629779 — Amit Patel, MD — A Phase 3, Ran­dom­ized, Dou­ble-Blind, Place­bo Con­trolled Study of PF-06821497 (Mevrome­to­stat) with Enza­lu­tamide in Metasta­t­ic Cas­tra­tion Resis­tant Prostate Cancer
• NCT06551324 — Amit Patel, MD — A Phase 3, Ran­dom­ized, Open-Label Study of PF-06821497 (Mevrome­to­stat) in Com­bi­na­tion with Enza­lu­tamide Com­pared with Enza­lu­tamide or Doc­etax­el in Par­tic­i­pants with Metasta­t­ic Cas­tra­tion Resis­tant Prostate Can­cer Pre­vi­ous­ly Treat­ed with Abi­raterone Acetate (MEVPRO‑1) 
• NCT06510374 — Amit Patel, MD — A Phase 3b, Ran­domised, Con­trolled Tri­al of Nad­o­fara­gene Firade­n­ovec vs. Obser­va­tion in Sub­jects with Inter­me­di­ate Risk (IR) Non-Mus­cle Inva­sive Blad­der Can­cer (NMIBC)
• NCT06545955 — Amit Patel, MD — A phase 2, ran­domised, mul­ti-cen­tre, open-label tri­al to eval­u­ate the safe­ty and effi­ca­cy of intrav­es­i­cal nad­o­fara­gene firade­n­ovec alone or in com­bi­na­tion with chemother­a­py (gem­c­itabine and doc­etax­el) or immunother­a­py (pem­brolizum­ab) in sub­jects with high-grade Bacil­lus Cal­mette-Guerin (BCG) unre­spon­sive non-mus­cle inva­sive blad­der can­cer (NMIBC)
• NCT06995677 — Amit Patel, MD — A Phase 2 Mul­ti­cen­ter, Open-Label Study Eval­u­at­ing the Effi­ca­cy and Safe­ty of TYRA-300 in Par­tic­i­pants with FGFR3 Altered Low Grade, Inter­me­di­ate Risk Non-Mus­cle Inva­sive Blad­der Can­cer (SURF302)
• NCT06111235 — Ranko Mio­ci­novic, MD — A Phase 3, Ran­dom­ized Study of Adju­vant Cre­tosti­mo­gene Grenade­norepvec ver­sus Obser­va­tion for the Treat­ment of Inter­me­di­ate Risk Non-Mus­cle Inva­sive Blad­der Can­cer (IR-NMIBC) Fol­low­ing Transurethral Resec­tion of Blad­der Tumor (TURBT) 
• NCT04165317 — Ranko Mio­ci­novic, MD — A Phase 3, Multi­na­tion­al, Ran­dom­ized, Open-Label, Three Par­al­lel-Arm Study of PF-06801591, an Anti-PD‑1 Anti­body, in Com­bi­na­tion With Bacil­lus Cal­mette-Guerin (BCG Induc­tion With or With­out BCG Main­te­nance) Ver­sus BCG (Induc­tion and Main­te­nance) in Par­tic­i­pants With High-Risk, BCG-Naïve Non-Mus­cle Inva­sive Blad­der Can­cer or PF-06801591 as a Sin­gle Agent in Par­tic­i­pants With BCG-Unre­spon­sive NMIBC
• NCT06567743 — Ranko Mio­ci­novic, MD — A Phase 2, Mul­ti-Arm, Mul­ti-Cohort, Open-Label Study to Eval­u­ate the Safe­ty and Effi­ca­cy of Cre­tosti­mo­gene Grenade­norepvec in Par­tic­i­pants With High-Risk Non-Mus­cle-Inva­sive Blad­der Can­cer (NMIBC)
• NCT04972097 — Ranko Mio­ci­novic, MD — Piv­otal Study of the NanoKnife Sys­tem for Abla­tion of Prostate Tis­sue in an Inter­me­di­ate-Risk Patient Population

Explore our cur­rent clin­i­cal tri­als and research programs >

Sup­port & recov­ery programs

Can­cer care is a whole-per­son jour­ney, and you’re nev­er alone in it. Our nurse nav­i­ga­tors, social work­ers, and sup­port spe­cial­ists help guide your care, con­nect you with com­mu­ni­ty resources, and pro­vide emo­tion­al, finan­cial, and pal­lia­tive sup­port when needed.

Learn more about our sup­port services >

How to get started

If you’re fac­ing a new diag­no­sis, a ris­ing PSA, or a treat­ment deci­sion, we can see you quick­ly — often with mul­ti­ple spe­cial­ists in one vis­it. Togeth­er, we’ll cre­ate a plan that’s per­son­al, prac­ti­cal, and aligned with your goals.

Sched­ule an Appoint­ment Online or Call 630−348−3600

If you’re seek­ing a sec­ond opin­ion, bring pri­or imag­ing and reports — we’ll review every­thing and guide you through next steps.